NCT06549855Recruiting
PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer
PD-1 Inhibitor Combined With Progesterone Treatment in Fertility Sparing Therapy for Mismatch Repair-deficient Endometrial Cancer
Source: ClinicalTrials.gov · Last updated 10 Aug 2026
Brief summary (registry, in English)
The objective of this study was to investigate the feasibility of a PD-1 inhibitor in combination with progesterone as a means of preserving fertility in patients with early-stage mismatch repair-deficient (MMRd) endometrial cancer who wish to preserve fertility.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 21 Jul 2024
- Start date
- 2 Sept 2024
- Primary completion date
- Jul 2029
- Lead sponsor
- Peking University People's Hospital
- Diseases
- Endometrial cancer
- NCT number
- NCT06549855
What you commit to
- Study type: Interventional
- Planned participants: 10
- From 2 Sept 2024 to the primary completion date, Jul 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Complicated with any other malignancy；
Other
- Stage IB(FIGO 2009) and above；
- Tumour differentiation of G3 or non-endometrioid adenocarcinoma；
- Contraindicated to conservative treatment or the use of pharmaceuticals.
- Contraindications to pregnancy, or judged by the researcher to be unfit for pregnancy or delivery.
Who the study is looking for
- Be between the ages of 18-45 years old;
- Stage IA (FIGO 2009) ;
- Confirmed diagnosis of endometrial adenocarcinoma G1-G2 based upon D\&C or hysteroscopy;
- Molecular classification of MMRd, determined by immunohistochemical (IHC) for MMR proteins and by the second generation sequencing (NGS) or microsatellite polymerase chain reaction (PCR);
- With a strong desire for fertility preservation;
- Sign the informed consent.
Age in the registry: 18 years to 45 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University People's Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.